For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
8
views
15
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      508
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Recurrent pityriasis rosea: A case report

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Pityriasis rosea is a papulosquamous skin disorder that occurs most commonly between the ages of 10 and 35 years. Recurrent pityriasis rosea is rare. We report a patient suffering from recurrent pityriasis rosea, whose etiology may be related to either vaccine-induced stimulation of the immune system, or some rare vaccine component(influenza A [H1N1] vaccine, hepatitis B vaccine). We believe that such a case is unique and it has not been reported previously. The patient was successfully treated with a combination of oral cetirizine, a topical steroid cream, and narrowband-ultraviolet B phototherapy. The symptoms of this disorder should be recognized by dermatologists.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology.

          Francesco Drago, Francesco Broccolo, Alfredo Rebora (2009)
          Pityriasis rosea is an acute, self-healing exanthem characterized by oval erythematous-squamous lesions of the trunk and limbs, that usually spares face, scalp, palms, and soles. Constitutional symptoms, which have the character of true prodromes; clinical features, which resemble those of the known exanthems; and many epidemiologic data all suggest an infectious origin. A host of infectious agents have been incriminated, but, recently, human herpesvirus 6 and 7 have been extensively studied. The goal of this review is to outline the epidemiologic, clinical, histologic, and ultrastructural features of pityriasis rosea, but mainly to stress its possible human herpesvirus nature. In addition, clues have been added to help the reader to go through the complex subtleties of the virologic investigation.
          Article 0 comments Cited 45 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Pityriasis Rosea: An Update on Etiopathogenesis and Management of Difficult Aspects

            Khushbu Mahajan, Vineet Relhan, Aditi Kochhar Relhan … (2016)
            Pityriasis rosea (PR) is a benign papulosquamous disorder seen commonly in clinical practice. Despite its prevalence and benign nature, there are still times when this common disorder presents in an uncommon way or course posing diagnostic or management problems for the treating physician. The etiopathogenesis of PR has always been a dilemma, and extensive research is going on to elicit the exact cause. This review focuses mainly on the difficult aspects of this benign common disorder such as etiopathogenesis, atypical manifestations, recurrent cases, differential diagnosis, therapy and pregnancy considerations. Although we could not find a black and white solution to all these problems, we have tried to compile the related literature to draw out some conclusions.
            Article 0 comments Cited 17 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Yellow fever vaccine-associated viscerotropic disease: current perspectives

              Roger Thomas (2016)
              Purpose To assess those published cases of yellow fever (YF) vaccine-associated viscerotropic disease that meet the Brighton Collaboration criteria and to assess the safety of YF vaccine with respect to viscerotropic disease. Literature search Ten electronic databases were searched with no restriction of date or language and reference lists of retrieved articles. Methods All abstracts and titles were independently read by two reviewers and data independently entered by two reviewers. Results All serious adverse events that met the Brighton Classification criteria were associated with first YF vaccinations. Sixty-two published cases (35 died) met the Brighton Collaboration viscerotropic criteria, with 32 from the US, six from Brazil, five from Peru, three from Spain, two from the People’s Republic of China, one each from Argentina, Australia, Belgium, Ecuador, France, Germany, Ireland, New Zealand, Portugal, and the UK, and four with no country stated. Two cases met both the viscerotropic and YF vaccine-associated neurologic disease criteria. Seventy cases proposed by authors as viscerotropic disease did not meet any Brighton Collaboration viscerotropic level of diagnostic certainty or any YF vaccine-associated viscerotropic disease causality criteria (37 died). Conclusion Viscerotropic disease is rare in the published literature and in pharmacovigilance databases. All published cases were from developing countries. Because the symptoms are usually very severe and life threatening, it is unlikely that cases would not come to medical attention (but might not be published). Because viscerotropic disease has a highly predictable pathologic course, it is likely that viscerotropic disease post-YF vaccine occurs in low-income countries with the same incidence as in developing countries. YF vaccine is a very safe vaccine that likely confers lifelong immunity.
              Article 0 comments Cited 13 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Hum Vaccin Immunother
                Journal ID (iso-abbrev): Hum Vaccin Immunother
                Journal ID (publisher-id): KHVI
                Journal ID (publisher-id): khvi20
                Title: Human Vaccines & Immunotherapeutics
                Publisher: Taylor & Francis
                ISSN (Print): 2164-5515
                ISSN (Electronic): 2164-554X
                Publication date Collection: 2018
                Publication date (Electronic): 21 December 2017
                Publication date PMC-release: 21 December 2017
                Volume: 14
                Issue: 4
                Pages: 1024-1026
                Affiliations
                [a ]Department of Dermatology, Qianfoshan Hospital, Shandong University , Jinan, Shandong, People's Republic of China
                [b ]Department of Clinical Medicine, Queen Mary School, Medical School, Nanchang University , Nanchang, Jiangxi, People's Republic of China
                [c ]Department of Clinical Medicine, Taishan Medical College , Tai'an, Shandong, People's Republic of China
                Author notes
                CONTACT Wenfei Li lwf888026@ 123456163.com Department of Dermatology, Qianfoshan Hospital, Shandong University , 16766 Jing-Shi Road, Jinan 250014, People's Republic of China
                [#]

                These authors contributed equally to this work.

                Article
                Publisher ID: 1409928
                DOI: 10.1080/21645515.2017.1409928
                PMC ID: 5893202
                PubMed ID: 29182459
                SO-VID: 0ac838ad-ba2a-4245-ab07-31912ba79600
                Copyright © © 2018 The Author(s). Published with license by Taylor & Francis
                License:

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Date received : 2 October 2017
                Date revision received : 29 October 2017
                Date accepted : 22 November 2017
                Page count
                Figures: 4, Tables: 0, Equations: 0, References: 15, Pages: 3
                Categories
                Subject: Case Report

                ScienceOpen disciplines: Molecular medicine
                Keywords: hepatitis b vaccine,induce,influenza a (h1n1) vaccine,pityriasis rosea,recurrent
                Data availability:
                ScienceOpen disciplines: Molecular medicine
                Keywords: hepatitis b vaccine, induce, influenza a (h1n1) vaccine, pityriasis rosea, recurrent

                Comments

                Comment on this article